Err-Cheng Chan

Title: Err-Cheng Chan: Innovator in Colorectal Cancer Detection

Introduction

Err-Cheng Chan is a notable inventor based in Tao-Yuan, Taiwan. He has made significant contributions to the field of medical diagnostics, particularly in the detection of colorectal cancer. His innovative work focuses on the development of serological markers that enhance the efficiency and sensitivity of cancer detection.

Latest Patents

Err-Cheng Chan holds a patent titled "Serological markers for detecting colorectal cancer and their application for inhibiting colorectal cancer cells." This patent describes the use of specific proteins, including phospholipid scramblase1 (PLSCR1), stomatin-like protein 2 (STOML2), and transport protein Sec61β (SEC61β), which show increased expression in the blood during the early stages of colorectal cancer. The detection of these proteins or their induced autoantibodies in blood samples is utilized for diagnosing colorectal cancer. Furthermore, these serological markers improve detection efficiency and sensitivity, aiding in prognosis prediction and the development of detection devices.

Career Highlights

Err-Cheng Chan is affiliated with Chang Gung University, where he continues to advance research in cancer diagnostics. His work has garnered attention for its potential impact on early cancer detection and treatment strategies.

Collaborations

Err-Cheng Chan collaborates with esteemed colleagues, including Kuei-Tien Chen and Jau-Song Yu, to further enhance the research and application of his innovative findings.

Conclusion

Err-Cheng Chan's contributions to the field of colorectal cancer detection exemplify the importance of innovation in medical research. His patented work not only aids in early diagnosis but also holds promise for improving patient outcomes.